Medicare Enrolled
Dr. Joseph My, D.O.
Hematology & Oncology · Stuart, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. My from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. My? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. My
Dr. Joseph My is a hematology & oncology in Stuart, FL, with 18 years in practice. Based on federal Medicare data, Dr. My performed 54,764 Medicare services across 4,048 unique beneficiaries.
Between the years covered by Open Payments, Dr. My received a total of $22,486 from 97 pharmaceutical and/or device companies across 1136 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. My is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 15% volume in FL$ $22,486 industry payments
Medicare Practice Summary
Medicare Utilization ↗54,764
Medicare services
Top 15% in FL for hematology & oncology
4,048
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,042 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) | 10,200 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 9,500 | $6 | $22 |
| Denosumab injection (Prolia/Xgeva) | 4,920 | $19 | $38 |
| Dexamethasone injection (steroid) | 4,557 | $0 | $2 |
| Iron infusion (Monoferric) | 4,500 | $17 | $51 |
| Complete blood count (CBC) with differential | 2,913 | $8 | $40 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,240 | $1 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 1,528 | $0 | $3 |
| Office visit, established patient (30-39 min) | 1,390 | $101 | $175 |
| Comprehensive metabolic blood panel | 1,342 | $10 | $40 |
| Injection, leucovorin calcium, per 50 mg | 1,060 | $3 | $31 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 893 | $3 | $48 |
| Injection, potassium chloride, per 2 meq | 685 | $0 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 683 | $107 | $330 |
| Injection, fluorouracil, 500 mg | 623 | $2 | $6 |
| Office visit, established patient (20-29 min) | 555 | $67 | $111 |
| Injection, carboplatin, 50 mg | 551 | $2 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 539 | $23 | $76 |
| Leuprolide injectable, camcevi, 1 mg | 462 | $59 | $117 |
| Injection, magnesium sulfate, per 500 mg | 434 | $1 | $3 |
| Drug injection, under skin or into muscle | 425 | $12 | $45 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 287 | $60 | $135 |
| Ferritin level test (iron stores) | 286 | $13 | $27 |
| Administration of additional new drug or substance into vein, 1 hour or less | 272 | $53 | $165 |
| Infusion, normal saline solution, 250 cc | 259 | $0 | $6 |
| Hospital follow-up visit, high complexity | 245 | $99 | $185 |
| Injection of additional new drug or substance into vein | 238 | $13 | $56 |
| Vitamin B-12 level test | 220 | $15 | $30 |
| Office visit, established patient, complex (40-54 min) | 220 | $147 | $251 |
| Thyroid stimulating hormone (TSH) test | 178 | $16 | $34 |
| Administration of chemotherapy into vein, each additional hour | 168 | $23 | $78 |
| Folic acid level test | 156 | $14 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 154 | $53 | $150 |
| PSA test (prostate cancer screening) | 150 | $18 | $37 |
| Injection, diphenhydramine hcl, up to 50 mg | 149 | $1 | $8 |
| Magnesium level test | 146 | $7 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 133 | $17 | $50 |
| Initial hospital admission, high complexity | 128 | $143 | $330 |
| New patient office visit, complex (60-74 min) | 104 | $173 | $364 |
| Carcinoembryonic antigen (cea) protein level | 101 | $19 | $38 |
| Lactate dehydrogenase (enzyme) level | 100 | $6 | $15 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 88 | $127 | $536 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 83 | $16 | $48 |
| New patient office visit (45-59 min) | 81 | $125 | $300 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 74 | $334 | $1,111 |
| Hospital follow-up visit, moderate complexity | 70 | $66 | $130 |
| Blood draw (venipuncture) | 66 | $8 | $15 |
| Irrigation of implanted venous access drug delivery device | 66 | $20 | $54 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 66 | $143 | $500 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 62 | $28 | $68 |
| Infusion into a vein for hydration, 31-60 minutes | 61 | $25 | $125 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 50 | $20 | $42 |
| Telephone medical discussion with physician, 5-10 minutes | 50 | $28 | $100 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 47 | $1 | $5 |
| Telephone medical discussion with physician, 11-20 minutes | 46 | $46 | $105 |
| Administration of additional new drug or substance into vein using push technique | 42 | $46 | $138 |
| Infusion into a vein for hydration, each additional hour | 35 | $11 | $40 |
| Phosphate level test | 28 | $5 | $11 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 21 | $137 | $354 |
| Initial hospital admission, moderate complexity | 19 | $109 | $250 |
| Office visit, established patient (10-19 min) | 15 | $41 | $103 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.6% high complexity
71.8% medium
17.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,486
Total received (2018-2024)
Avg $3,212/year across 7 years
Top 24% in FL for hematology & oncology
97
Companies
1,136
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,106 (98.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$380 (1.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,960
2023$4,304
2022$3,041
2021$2,811
2020$2,483
2019$3,883
2018$2,004
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,851
PFIZER INC.
$1,841
Janssen Biotech, Inc.
$1,801
E.R. Squibb & Sons, L.L.C.
$1,776
Amgen Inc.
$972
Genentech USA, Inc.
$948
Celgene Corporation
$895
GENZYME CORPORATION
$731
Novartis Pharmaceuticals Corporation
$725
Astellas Pharma US Inc
$722
Merck Sharp & Dohme Corporation
$655
Incyte Corporation
$560
Merck Sharp & Dohme LLC
$547
Seagen Inc.
$542
Lilly USA, LLC
$494
Ipsen Biopharmaceuticals, Inc
$452
Daiichi Sankyo Inc.
$421
GlaxoSmithKline, LLC.
$402
Bayer HealthCare Pharmaceuticals Inc.
$401
Coherus Biosciences Inc.
$296
Pharmacyclics LLC, An AbbVie Company
$222
Takeda Pharmaceuticals U.S.A., Inc.
$222
Eisai Inc.
$218
ABBVIE INC.
$216
Seattle Genetics, Inc.
$198
JAZZ PHARMACEUTICALS INC.
$194
Foundation Medicine, Inc.
$193
Karyopharm Therapeutics Inc.
$185
Medtronic, Inc.
$175
Dova Pharmaceuticals
$158
Regeneron Healthcare Solutions, Inc.
$151
BeiGene USA, Inc.
$148
EISAI INC.
$145
Alexion Pharmaceuticals, Inc.
$129
ARRAY BIOPHARMA INC
$120
Taiho Oncology, Inc.
$118
Pharmacyclics LLC, an AbbVie Company
$116
Tempus AI, Inc
$99
SEAGEN INC.
$99
Exelixis Inc.
$93
Puma Biotechnology, Inc.
$86
Mirati Therapeutics, Inc.
$86
Kyowa Kirin, Inc.
$82
EMD Serono, Inc.
$79
TAIHO ONCOLOGY, INC.
$78
Rigel Pharmaceuticals, Inc.
$77
AbbVie Inc.
$77
SERVIER PHARMACEUTICALS LLC
$74
AbbVie, Inc.
$74
Sobi, Inc
$73
PharmaEssentia USA Corporation
$72
PUMA BIOTECHNOLOGY, INC.
$69
SOBI, INC
$64
Boehringer Ingelheim Pharmaceuticals, Inc.
$61
Bayer Healthcare Pharmaceuticals Inc.
$59
Sumitomo Pharma America, Inc.
$57
Myriad Genetic Laboratories, Inc.
$57
Epizyme, Inc.,
$56
MorphoSys, US Inc.
$54
Clovis Oncology, Inc.
$48
Fennec Pharmaceuticals, Inc.
$47
Agios Pharmaceuticals, Inc.
$40
ACCORD HEALTHCARE, INC.
$40
Lexicon Pharmaceuticals, Inc.
$39
RECORDATI_RARE_DISEASES_INC.
$35
Sun Pharmaceutical Industries Inc.
$34
Verastem, Inc.
$34
Kite Pharma, Inc.
$34
SUN PHARMACEUTICAL INDUSTRIES INC.
$32
MEDIVATION FIELD SOLUTIONS LLC
$31
Mylan Institutional Inc.
$25
Emmaus Medical, Inc.
$23
Shire North American Group Inc
$23
Gilead Sciences, Inc.
$23
CTI BioPharma Corp.
$22
Secura Bio, Inc.
$21
SANOFI-AVENTIS U.S. LLC
$21
TESARO, Inc.
$21
Stemline Therapeutics Inc.
$21
Heron Therapeutics, Inc.
$21
Acrotech Biopharma Inc.
$20
EUSA Pharma (US) LLC
$20
Apellis Pharmaceuticals, Inc.
$20
Aurobindo Pharma USA, Inc.
$19
Aveo Pharmaceuticals, Inc.
$19
Genmab U.S., Inc.
$19
Blue Earth Diagnostics Limited
$18
Array BioPharma Inc.
$18
ADC Therapeutics America, Inc.
$18
INSYS Therapeutics Inc
$17
Partner Therapeutics, Inc.
$15
Pharmacosmos Therapeutics Inc.
$15
Novocure Inc.
$15
TerSera Therapeutics LLC
$15
Myovant Sciences Inc.
$15
Acceleron Pharma, Inc.
$14
TOLMAR Pharmaceuticals, Inc.
$13
Top 3 companies account for 24.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Aliqopa · Avastin · BESREMI · BLENREP · BOSULIF · BRACAnalysis CDx · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CAMCEVI · CARBAGLU · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EVENITY · Empaveli · Endari · Enhertu · Epkinly · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Farydak · GAMMAGARD · GAZYVA · GILOTRIF · Gazyva · HYQVIA · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LEUKINE · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lupron Depot · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONIVYDE · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OSTEOCOOL RF ABLATION SYSTEM · OXBRYTA · Odomzo · Ogivri · Optune · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POSLUMA · PROMACTA · PYRUKYND · Padcev · Pedmark · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · REBLOZYL · RETEVMO · RYBREVANT · RYZNEUTA · Reblozyl · Revlimid · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYLVANT · SYNDROS · Somatuline Depot · Stivarga · Sylvant · TABRECTA · TAGRISSO · TALVEY · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vitrakvi · Vonjo · XALKORI · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xofigo · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $41 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
18
Per 100K population
11.2
County median income
$80,701
Nearest hospital
CLEVELAND CLINIC MARTIN NORTH HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. My is a mixed practice specialist, with above-average Medicare volume (top 15% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. My experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. My performed 10,200 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. My receive payments from pharmaceutical companies?
Yes. Dr. My received a total of $22,486 from 97 companies across 1,136 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. My's costs compare to other hematology & oncologys in Stuart?
Dr. My's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. My) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Stuart
Browse hematology & oncologys in Stuart ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology